Cuba aspires to vaccinate its entire population
BY: Alexis Bandrich Vega* PEJOURNAL - Soberana 01 has been called the phase I-II clinical trial that will validate the efficacy of the Cuban vaccine candidate against COVID-19, which began to be applied to a group of volunteers on August 24. The works are developed by the Finlay Vaccine Institute, which has more than 30 years of experience in vaccine development and a long history of cooperation with the Pasteur Institute of Iran. Initially, work began with 20 volunteers from two population groups, between 19 and 59 years old and another from 60 to 80, to whom different doses of…
